Plain-English translation of NCT06044025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether and can help manage prostate cancer that is progressing despite hormone therapy. is an FDA-approved diabetes medication, and is an over-the-counter supplement with anti-inflammatory properties. Researchers want to see if these two treatments, combined with dietary advice, can help slow cancer growth and be practical for patients to use alongside their regular care.
Some men's prostate cancer continues to progress even when they are receiving hormone therapy, and there are limited options to help slow that progression. This study explores whether the medication combined with might offer a practical way to support standard cancer treatment and possibly help keep cancer dormant longer.
You likely qualify if…
You likely don't qualify if…
You would start taking within 7 days of joining, beginning at 500 mg twice daily with meals, then gradually increasing to 1,000 mg twice daily over about 4 weeks. After 2 weeks, you would also begin taking at 1,500 mg daily with meals (reduced to 1,000 mg if you experience stomach discomfort). You would receive dietary consultation and continue your regular cancer care and blood tests. The study will also collect extra blood samples and stool samples to look for signs of how the treatment is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States